Work

First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.5552

Authors: Johanna C. Bendell, Lawrence Fong, Mark N. Stein, Tomasz M. Beer, Ashley Ross, Xin Gao, Aaron Weitzman, Richard Austin, Vaishnavi Ganti, Che-Leung Law, Bryan Lemon, Holger Wesche, Johann S. De Bono

Institutions: Sarah Cannon, Tennessee Oncology, University of California, San Francisco, Columbia University Irving Medical Center, Oregon Health & Science University, OHSU Knight Cancer Institute, Mary Crowley Cancer Research Center, Massachusetts General Hospital, Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029959649

Cites:

Cited by: 20

Related to: 10